nodes	percent_of_prediction	percent_of_DWPC	metapath
Norfloxacin—CYP1A1—chronic obstructive pulmonary disease	0.227	0.509	CbGaD
Norfloxacin—CYP1A2—chronic obstructive pulmonary disease	0.219	0.491	CbGaD
Norfloxacin—SLC22A5—Tiotropium—chronic obstructive pulmonary disease	0.0843	0.208	CbGbCtD
Norfloxacin—CYP2A6—Formoterol—chronic obstructive pulmonary disease	0.0719	0.178	CbGbCtD
Norfloxacin—CYP2A6—Arformoterol—chronic obstructive pulmonary disease	0.0719	0.178	CbGbCtD
Norfloxacin—CYP2A6—Montelukast—chronic obstructive pulmonary disease	0.0545	0.135	CbGbCtD
Norfloxacin—CYP2A6—Prednisolone—chronic obstructive pulmonary disease	0.032	0.0789	CbGbCtD
Norfloxacin—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0233	0.0576	CbGbCtD
Norfloxacin—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.019	0.0468	CbGbCtD
Norfloxacin—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0128	0.0316	CbGbCtD
Norfloxacin—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0122	0.0302	CbGbCtD
Norfloxacin—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0109	0.0269	CbGbCtD
Norfloxacin—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00639	0.0158	CbGbCtD
Norfloxacin—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00604	0.0149	CbGbCtD
Norfloxacin—TOP2A—Salmeterol—Salbutamol—chronic obstructive pulmonary disease	0.00139	0.807	CbGdCrCtD
Norfloxacin—Pefloxacin—CYP1A2—chronic obstructive pulmonary disease	0.000607	0.192	CrCbGaD
Norfloxacin—Enoxacin—CYP1A2—chronic obstructive pulmonary disease	0.000568	0.18	CrCbGaD
Norfloxacin—Gatifloxacin—ALB—chronic obstructive pulmonary disease	0.000463	0.146	CrCbGaD
Norfloxacin—Lomefloxacin—CYP1A2—chronic obstructive pulmonary disease	0.00043	0.136	CrCbGaD
Norfloxacin—Levofloxacin—CYP1A2—chronic obstructive pulmonary disease	0.000368	0.116	CrCbGaD
Norfloxacin—Ofloxacin—CYP1A2—chronic obstructive pulmonary disease	0.000368	0.116	CrCbGaD
Norfloxacin—Ciprofloxacin—CYP1A2—chronic obstructive pulmonary disease	0.000355	0.112	CrCbGaD
Norfloxacin—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000232	0.00209	CcSEcCtD
Norfloxacin—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000232	0.00209	CcSEcCtD
Norfloxacin—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00023	0.00208	CcSEcCtD
Norfloxacin—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.000229	0.00206	CcSEcCtD
Norfloxacin—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000227	0.00205	CcSEcCtD
Norfloxacin—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000227	0.00205	CcSEcCtD
Norfloxacin—Dermatitis bullous—Prednisolone—chronic obstructive pulmonary disease	0.000227	0.00205	CcSEcCtD
Norfloxacin—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000226	0.00204	CcSEcCtD
Norfloxacin—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000226	0.00204	CcSEcCtD
Norfloxacin—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000225	0.00203	CcSEcCtD
Norfloxacin—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.00202	CcSEcCtD
Norfloxacin—Anaphylactoid reaction—Prednisolone—chronic obstructive pulmonary disease	0.000224	0.00202	CcSEcCtD
Norfloxacin—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000223	0.00201	CcSEcCtD
Norfloxacin—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000223	0.00201	CcSEcCtD
Norfloxacin—Vasculitis—Prednisone—chronic obstructive pulmonary disease	0.000222	0.00201	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000222	0.002	CcSEcCtD
Norfloxacin—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000221	0.002	CcSEcCtD
Norfloxacin—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000221	0.002	CcSEcCtD
Norfloxacin—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000221	0.002	CcSEcCtD
Norfloxacin—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000221	0.00199	CcSEcCtD
Norfloxacin—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00022	0.00199	CcSEcCtD
Norfloxacin—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00199	CcSEcCtD
Norfloxacin—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00199	CcSEcCtD
Norfloxacin—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00199	CcSEcCtD
Norfloxacin—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000219	0.00197	CcSEcCtD
Norfloxacin—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000219	0.00197	CcSEcCtD
Norfloxacin—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000217	0.00196	CcSEcCtD
Norfloxacin—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.000217	0.00196	CcSEcCtD
Norfloxacin—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000216	0.00195	CcSEcCtD
Norfloxacin—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000214	0.00194	CcSEcCtD
Norfloxacin—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000213	0.00192	CcSEcCtD
Norfloxacin—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000213	0.00192	CcSEcCtD
Norfloxacin—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000213	0.00192	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.00191	CcSEcCtD
Norfloxacin—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000209	0.00189	CcSEcCtD
Norfloxacin—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000209	0.00188	CcSEcCtD
Norfloxacin—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000208	0.00188	CcSEcCtD
Norfloxacin—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.00188	CcSEcCtD
Norfloxacin—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000205	0.00185	CcSEcCtD
Norfloxacin—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000205	0.00185	CcSEcCtD
Norfloxacin—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000205	0.00185	CcSEcCtD
Norfloxacin—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.00185	CcSEcCtD
Norfloxacin—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.00185	CcSEcCtD
Norfloxacin—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000205	0.00185	CcSEcCtD
Norfloxacin—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.00185	CcSEcCtD
Norfloxacin—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000204	0.00185	CcSEcCtD
Norfloxacin—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000204	0.00184	CcSEcCtD
Norfloxacin—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000204	0.00184	CcSEcCtD
Norfloxacin—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.00184	CcSEcCtD
Norfloxacin—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000204	0.00184	CcSEcCtD
Norfloxacin—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000204	0.00184	CcSEcCtD
Norfloxacin—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000201	0.00181	CcSEcCtD
Norfloxacin—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000201	0.00181	CcSEcCtD
Norfloxacin—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000201	0.00181	CcSEcCtD
Norfloxacin—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000201	0.00181	CcSEcCtD
Norfloxacin—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000201	0.00181	CcSEcCtD
Norfloxacin—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.0002	0.00181	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000199	0.0018	CcSEcCtD
Norfloxacin—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.00177	CcSEcCtD
Norfloxacin—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.00177	CcSEcCtD
Norfloxacin—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000197	0.00177	CcSEcCtD
Norfloxacin—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000197	0.00177	CcSEcCtD
Norfloxacin—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000194	0.00175	CcSEcCtD
Norfloxacin—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000194	0.00175	CcSEcCtD
Norfloxacin—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000194	0.00175	CcSEcCtD
Norfloxacin—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000194	0.00175	CcSEcCtD
Norfloxacin—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.00174	CcSEcCtD
Norfloxacin—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000193	0.00174	CcSEcCtD
Norfloxacin—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000193	0.00174	CcSEcCtD
Norfloxacin—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000193	0.00174	CcSEcCtD
Norfloxacin—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00019	0.00172	CcSEcCtD
Norfloxacin—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000189	0.00171	CcSEcCtD
Norfloxacin—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000189	0.0017	CcSEcCtD
Norfloxacin—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000186	0.00168	CcSEcCtD
Norfloxacin—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.00168	CcSEcCtD
Norfloxacin—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.00168	CcSEcCtD
Norfloxacin—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000184	0.00166	CcSEcCtD
Norfloxacin—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000183	0.00165	CcSEcCtD
Norfloxacin—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000179	0.00162	CcSEcCtD
Norfloxacin—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.00162	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000179	0.00162	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000179	0.00162	CcSEcCtD
Norfloxacin—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.0016	CcSEcCtD
Norfloxacin—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000178	0.0016	CcSEcCtD
Norfloxacin—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.0016	CcSEcCtD
Norfloxacin—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000177	0.0016	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000175	0.00158	CcSEcCtD
Norfloxacin—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000175	0.00158	CcSEcCtD
Norfloxacin—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.00158	CcSEcCtD
Norfloxacin—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.00158	CcSEcCtD
Norfloxacin—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000175	0.00158	CcSEcCtD
Norfloxacin—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000174	0.00157	CcSEcCtD
Norfloxacin—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000173	0.00156	CcSEcCtD
Norfloxacin—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000173	0.00156	CcSEcCtD
Norfloxacin—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000173	0.00156	CcSEcCtD
Norfloxacin—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000172	0.00156	CcSEcCtD
Norfloxacin—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00155	CcSEcCtD
Norfloxacin—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000171	0.00154	CcSEcCtD
Norfloxacin—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00017	0.00153	CcSEcCtD
Norfloxacin—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000169	0.00153	CcSEcCtD
Norfloxacin—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000169	0.00153	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00153	CcSEcCtD
Norfloxacin—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000168	0.00152	CcSEcCtD
Norfloxacin—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.00152	CcSEcCtD
Norfloxacin—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.00152	CcSEcCtD
Norfloxacin—TOP2A—Methyltestosterone—Prednisone—chronic obstructive pulmonary disease	0.000168	0.0975	CbGdCrCtD
Norfloxacin—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.0015	CcSEcCtD
Norfloxacin—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000166	0.0015	CcSEcCtD
Norfloxacin—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.00149	CcSEcCtD
Norfloxacin—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00149	CcSEcCtD
Norfloxacin—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.00149	CcSEcCtD
Norfloxacin—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000164	0.00148	CcSEcCtD
Norfloxacin—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.00148	CcSEcCtD
Norfloxacin—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.00148	CcSEcCtD
Norfloxacin—TOP2A—Methyltestosterone—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.0951	CbGdCrCtD
Norfloxacin—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.00147	CcSEcCtD
Norfloxacin—CYP1A1—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000163	0.00494	CbGpPWpGaD
Norfloxacin—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000163	0.00493	CbGpPWpGaD
Norfloxacin—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000163	0.00147	CcSEcCtD
Norfloxacin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000163	0.00147	CcSEcCtD
Norfloxacin—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.00146	CcSEcCtD
Norfloxacin—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.00146	CcSEcCtD
Norfloxacin—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000162	0.00146	CcSEcCtD
Norfloxacin—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000162	0.00146	CcSEcCtD
Norfloxacin—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00146	CcSEcCtD
Norfloxacin—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000161	0.00145	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000161	0.00145	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.00145	CcSEcCtD
Norfloxacin—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00016	0.00485	CbGpPWpGaD
Norfloxacin—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.00144	CcSEcCtD
Norfloxacin—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00143	CcSEcCtD
Norfloxacin—CYP2A6—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000159	0.0048	CbGpPWpGaD
Norfloxacin—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000157	0.00142	CcSEcCtD
Norfloxacin—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000157	0.00142	CcSEcCtD
Norfloxacin—CYP3A7—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000157	0.00474	CbGpPWpGaD
Norfloxacin—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000156	0.00473	CbGpPWpGaD
Norfloxacin—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000156	0.00141	CcSEcCtD
Norfloxacin—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000156	0.00141	CcSEcCtD
Norfloxacin—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000155	0.0014	CcSEcCtD
Norfloxacin—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.0014	CcSEcCtD
Norfloxacin—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.0014	CcSEcCtD
Norfloxacin—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000155	0.0014	CcSEcCtD
Norfloxacin—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000155	0.0014	CcSEcCtD
Norfloxacin—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000154	0.00139	CcSEcCtD
Norfloxacin—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000154	0.00139	CcSEcCtD
Norfloxacin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000153	0.00139	CcSEcCtD
Norfloxacin—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000153	0.00138	CcSEcCtD
Norfloxacin—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000153	0.00138	CcSEcCtD
Norfloxacin—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.00138	CcSEcCtD
Norfloxacin—CYP1A1—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000153	0.00462	CbGpPWpGaD
Norfloxacin—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000153	0.00138	CcSEcCtD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000153	0.00462	CbGpPWpGaD
Norfloxacin—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000152	0.00137	CcSEcCtD
Norfloxacin—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000152	0.00137	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00137	CcSEcCtD
Norfloxacin—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00015	0.00455	CbGpPWpGaD
Norfloxacin—Irritability—Prednisone—chronic obstructive pulmonary disease	0.00015	0.00136	CcSEcCtD
Norfloxacin—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.00133	CcSEcCtD
Norfloxacin—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000147	0.00446	CbGpPWpGaD
Norfloxacin—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.00132	CcSEcCtD
Norfloxacin—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.00132	CcSEcCtD
Norfloxacin—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000145	0.00131	CcSEcCtD
Norfloxacin—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000145	0.00131	CcSEcCtD
Norfloxacin—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000145	0.00131	CcSEcCtD
Norfloxacin—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000144	0.0013	CcSEcCtD
Norfloxacin—CYP2A6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000144	0.00435	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000143	0.00432	CbGpPWpGaD
Norfloxacin—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000142	0.00128	CcSEcCtD
Norfloxacin—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000142	0.00428	CbGpPWpGaD
Norfloxacin—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000141	0.00127	CcSEcCtD
Norfloxacin—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000141	0.00127	CcSEcCtD
Norfloxacin—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.00014	0.00425	CbGpPWpGaD
Norfloxacin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.00014	0.00423	CbGpPWpGaD
Norfloxacin—TOP2A—Gastric Cancer Network 2—TP53—chronic obstructive pulmonary disease	0.00014	0.00423	CbGpPWpGaD
Norfloxacin—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000139	0.00126	CcSEcCtD
Norfloxacin—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000139	0.00126	CcSEcCtD
Norfloxacin—CYP3A7—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000139	0.00419	CbGpPWpGaD
Norfloxacin—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000138	0.00125	CcSEcCtD
Norfloxacin—CYP3A5—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000138	0.00417	CbGpPWpGaD
Norfloxacin—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000137	0.00123	CcSEcCtD
Norfloxacin—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000136	0.00123	CcSEcCtD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000136	0.00412	CbGpPWpGaD
Norfloxacin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000136	0.00411	CbGpPWpGaD
Norfloxacin—CYP1A1—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000135	0.00408	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—SLC6A4—chronic obstructive pulmonary disease	0.000135	0.00407	CbGpPWpGaD
Norfloxacin—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000135	0.00121	CcSEcCtD
Norfloxacin—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000135	0.00121	CcSEcCtD
Norfloxacin—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000133	0.0012	CcSEcCtD
Norfloxacin—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.0012	CcSEcCtD
Norfloxacin—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000132	0.00399	CbGpPWpGaD
Norfloxacin—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000132	0.00119	CcSEcCtD
Norfloxacin—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000131	0.00119	CcSEcCtD
Norfloxacin—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.00118	CcSEcCtD
Norfloxacin—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.00013	0.00395	CbGpPWpGaD
Norfloxacin—CYP1A1—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.00013	0.00394	CbGpPWpGaD
Norfloxacin—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00013	0.00117	CcSEcCtD
Norfloxacin—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00013	0.00117	CcSEcCtD
Norfloxacin—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000129	0.00389	CbGpPWpGaD
Norfloxacin—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000127	0.00115	CcSEcCtD
Norfloxacin—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000127	0.00115	CcSEcCtD
Norfloxacin—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.00115	CcSEcCtD
Norfloxacin—CYP2A6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000127	0.00384	CbGpPWpGaD
Norfloxacin—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000125	0.00113	CcSEcCtD
Norfloxacin—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000125	0.00113	CcSEcCtD
Norfloxacin—Rash—Formoterol—chronic obstructive pulmonary disease	0.000124	0.00112	CcSEcCtD
Norfloxacin—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000124	0.00112	CcSEcCtD
Norfloxacin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000124	0.00112	CcSEcCtD
Norfloxacin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000124	0.00112	CcSEcCtD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000124	0.00375	CbGpPWpGaD
Norfloxacin—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000124	0.00374	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000124	0.00374	CbGpPWpGaD
Norfloxacin—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000123	0.00111	CcSEcCtD
Norfloxacin—Headache—Formoterol—chronic obstructive pulmonary disease	0.000123	0.00111	CcSEcCtD
Norfloxacin—TOP2A—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000123	0.00372	CbGpPWpGaD
Norfloxacin—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000123	0.00111	CcSEcCtD
Norfloxacin—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000123	0.00111	CcSEcCtD
Norfloxacin—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000122	0.00111	CcSEcCtD
Norfloxacin—Rash—Montelukast—chronic obstructive pulmonary disease	0.000121	0.0011	CcSEcCtD
Norfloxacin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000121	0.00109	CcSEcCtD
Norfloxacin—Headache—Montelukast—chronic obstructive pulmonary disease	0.000121	0.00109	CcSEcCtD
Norfloxacin—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.00012	0.00108	CcSEcCtD
Norfloxacin—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.00108	CcSEcCtD
Norfloxacin—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000119	0.00107	CcSEcCtD
Norfloxacin—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000119	0.00107	CcSEcCtD
Norfloxacin—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.00107	CcSEcCtD
Norfloxacin—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.00106	CcSEcCtD
Norfloxacin—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.00106	CcSEcCtD
Norfloxacin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.00106	CcSEcCtD
Norfloxacin—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000117	0.00105	CcSEcCtD
Norfloxacin—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000117	0.00105	CcSEcCtD
Norfloxacin—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000117	0.00353	CbGpPWpGaD
Norfloxacin—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000116	0.00105	CcSEcCtD
Norfloxacin—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000114	0.00103	CcSEcCtD
Norfloxacin—CYP3A7—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000114	0.00344	CbGpPWpGaD
Norfloxacin—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000114	0.00344	CbGpPWpGaD
Norfloxacin—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000113	0.00343	CbGpPWpGaD
Norfloxacin—CYP2A6—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000113	0.00342	CbGpPWpGaD
Norfloxacin—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000113	0.00102	CcSEcCtD
Norfloxacin—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00011	0.000995	CcSEcCtD
Norfloxacin—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000109	0.00331	CbGpPWpGaD
Norfloxacin—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000109	0.00331	CbGpPWpGaD
Norfloxacin—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000978	CcSEcCtD
Norfloxacin—CYP1A1—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000107	0.00324	CbGpPWpGaD
Norfloxacin—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000961	CcSEcCtD
Norfloxacin—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000961	CcSEcCtD
Norfloxacin—CYP2A6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.00316	CbGpPWpGaD
Norfloxacin—CYP2A6—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000103	0.00313	CbGpPWpGaD
Norfloxacin—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000929	CcSEcCtD
Norfloxacin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000102	0.0031	CbGpPWpGaD
Norfloxacin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000101	0.00307	CbGpPWpGaD
Norfloxacin—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.0001	0.00303	CbGpPWpGaD
Norfloxacin—CYP3A7—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.0001	0.00303	CbGpPWpGaD
Norfloxacin—CYP3A7—Biological oxidations—GCLC—chronic obstructive pulmonary disease	9.9e-05	0.003	CbGpPWpGaD
Norfloxacin—CYP2A6—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	9.8e-05	0.00297	CbGpPWpGaD
Norfloxacin—Insomnia—Prednisolone—chronic obstructive pulmonary disease	9.63e-05	0.000869	CcSEcCtD
Norfloxacin—CYP2A6—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	9.61e-05	0.00291	CbGpPWpGaD
Norfloxacin—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	9.56e-05	0.000863	CcSEcCtD
Norfloxacin—Erythema—Prednisone—chronic obstructive pulmonary disease	9.48e-05	0.000856	CcSEcCtD
Norfloxacin—CYP2A6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	9.18e-05	0.00278	CbGpPWpGaD
Norfloxacin—CYP2A6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	9.07e-05	0.00275	CbGpPWpGaD
Norfloxacin—Vision blurred—Prednisone—chronic obstructive pulmonary disease	8.93e-05	0.000806	CcSEcCtD
Norfloxacin—CYP1A1—PPARA activates gene expression—CTGF—chronic obstructive pulmonary disease	8.82e-05	0.00267	CbGpPWpGaD
Norfloxacin—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	8.77e-05	0.000792	CcSEcCtD
Norfloxacin—Agitation—Prednisone—chronic obstructive pulmonary disease	8.71e-05	0.000786	CcSEcCtD
Norfloxacin—Angioedema—Prednisone—chronic obstructive pulmonary disease	8.66e-05	0.000782	CcSEcCtD
Norfloxacin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—chronic obstructive pulmonary disease	8.63e-05	0.00261	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	8.61e-05	0.0026	CbGpPWpGaD
Norfloxacin—Vertigo—Prednisone—chronic obstructive pulmonary disease	8.52e-05	0.000769	CcSEcCtD
Norfloxacin—Urticaria—Prednisolone—chronic obstructive pulmonary disease	8.46e-05	0.000763	CcSEcCtD
Norfloxacin—CYP3A7—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.32e-05	0.00252	CbGpPWpGaD
Norfloxacin—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.23e-05	0.00249	CbGpPWpGaD
Norfloxacin—Convulsion—Prednisone—chronic obstructive pulmonary disease	8.21e-05	0.000741	CcSEcCtD
Norfloxacin—CYP3A7—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	8.21e-05	0.00248	CbGpPWpGaD
Norfloxacin—Arthralgia—Prednisone—chronic obstructive pulmonary disease	8.07e-05	0.000728	CcSEcCtD
Norfloxacin—Myalgia—Prednisone—chronic obstructive pulmonary disease	8.07e-05	0.000728	CcSEcCtD
Norfloxacin—Anxiety—Prednisone—chronic obstructive pulmonary disease	8.04e-05	0.000726	CcSEcCtD
Norfloxacin—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	8.03e-05	0.00243	CbGpPWpGaD
Norfloxacin—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	7.84e-05	0.000708	CcSEcCtD
Norfloxacin—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	7.74e-05	0.000698	CcSEcCtD
Norfloxacin—Oedema—Prednisone—chronic obstructive pulmonary disease	7.74e-05	0.000698	CcSEcCtD
Norfloxacin—TOP2A—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	7.67e-05	0.00232	CbGpPWpGaD
Norfloxacin—CYP2A6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	7.63e-05	0.00231	CbGpPWpGaD
Norfloxacin—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	7.56e-05	0.00229	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	7.56e-05	0.00229	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	7.56e-05	0.00229	CbGpPWpGaD
Norfloxacin—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	7.48e-05	0.000675	CcSEcCtD
Norfloxacin—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	7.45e-05	0.00226	CbGpPWpGaD
Norfloxacin—Anorexia—Prednisone—chronic obstructive pulmonary disease	7.38e-05	0.000666	CcSEcCtD
Norfloxacin—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	7.37e-05	0.00223	CbGpPWpGaD
Norfloxacin—CYP2A6—Fluoropyrimidine Activity—TP53—chronic obstructive pulmonary disease	7.35e-05	0.00222	CbGpPWpGaD
Norfloxacin—CYP2A6—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	7.25e-05	0.00219	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.24e-05	0.00219	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.15e-05	0.00216	CbGpPWpGaD
Norfloxacin—CYP2A6—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	7.15e-05	0.00216	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	7.15e-05	0.00216	CbGpPWpGaD
Norfloxacin—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	7.07e-05	0.00214	CbGpPWpGaD
Norfloxacin—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	7.05e-05	0.000636	CcSEcCtD
Norfloxacin—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.04e-05	0.000636	CcSEcCtD
Norfloxacin—Insomnia—Prednisone—chronic obstructive pulmonary disease	7e-05	0.000632	CcSEcCtD
Norfloxacin—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	6.95e-05	0.000627	CcSEcCtD
Norfloxacin—CYP3A7—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.94e-05	0.0021	CbGpPWpGaD
Norfloxacin—CYP3A7—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.84e-05	0.00207	CbGpPWpGaD
Norfloxacin—CYP1A1—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.84e-05	0.00207	CbGpPWpGaD
Norfloxacin—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	6.81e-05	0.000615	CcSEcCtD
Norfloxacin—CYP1A1—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.76e-05	0.00205	CbGpPWpGaD
Norfloxacin—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	6.73e-05	0.000607	CcSEcCtD
Norfloxacin—Rash—Prednisolone—chronic obstructive pulmonary disease	6.71e-05	0.000606	CcSEcCtD
Norfloxacin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	6.71e-05	0.000605	CcSEcCtD
Norfloxacin—Fatigue—Prednisone—chronic obstructive pulmonary disease	6.67e-05	0.000602	CcSEcCtD
Norfloxacin—Headache—Prednisolone—chronic obstructive pulmonary disease	6.67e-05	0.000602	CcSEcCtD
Norfloxacin—CYP2A6—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	6.66e-05	0.00202	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	6.64e-05	0.00201	CbGpPWpGaD
Norfloxacin—Constipation—Prednisone—chronic obstructive pulmonary disease	6.62e-05	0.000597	CcSEcCtD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	6.56e-05	0.00199	CbGpPWpGaD
Norfloxacin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	6.49e-05	0.00197	CbGpPWpGaD
Norfloxacin—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	6.41e-05	0.00194	CbGpPWpGaD
Norfloxacin—CYP3A7—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.38e-05	0.00193	CbGpPWpGaD
Norfloxacin—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	6.38e-05	0.000575	CcSEcCtD
Norfloxacin—CYP2A6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.36e-05	0.00193	CbGpPWpGaD
Norfloxacin—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.33e-05	0.000571	CcSEcCtD
Norfloxacin—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.32e-05	0.000571	CcSEcCtD
Norfloxacin—CYP3A7—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.29e-05	0.0019	CbGpPWpGaD
Norfloxacin—Urticaria—Prednisone—chronic obstructive pulmonary disease	6.15e-05	0.000555	CcSEcCtD
Norfloxacin—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	6.12e-05	0.000552	CcSEcCtD
Norfloxacin—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	6.12e-05	0.000552	CcSEcCtD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—chronic obstructive pulmonary disease	6.11e-05	0.00185	CbGpPWpGaD
Norfloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	6.11e-05	0.00185	CbGpPWpGaD
Norfloxacin—CYP3A7—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.05e-05	0.00183	CbGpPWpGaD
Norfloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	6.03e-05	0.00183	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	6.02e-05	0.00182	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.01e-05	0.00182	CbGpPWpGaD
Norfloxacin—CYP3A7—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.96e-05	0.0018	CbGpPWpGaD
Norfloxacin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—chronic obstructive pulmonary disease	5.95e-05	0.0018	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.93e-05	0.0018	CbGpPWpGaD
Norfloxacin—CYP2A6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.85e-05	0.00177	CbGpPWpGaD
Norfloxacin—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	5.84e-05	0.00177	CbGpPWpGaD
Norfloxacin—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	5.7e-05	0.000515	CcSEcCtD
Norfloxacin—CYP1A1—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.68e-05	0.00172	CbGpPWpGaD
Norfloxacin—CYP1A1—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.6e-05	0.0017	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	5.55e-05	0.00168	CbGpPWpGaD
Norfloxacin—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.55e-05	0.000501	CcSEcCtD
Norfloxacin—CYP2A6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.54e-05	0.00168	CbGpPWpGaD
Norfloxacin—Pruritus—Prednisone—chronic obstructive pulmonary disease	5.47e-05	0.000494	CcSEcCtD
Norfloxacin—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.29e-05	0.000478	CcSEcCtD
Norfloxacin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	5.26e-05	0.00159	CbGpPWpGaD
Norfloxacin—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	5.17e-05	0.00156	CbGpPWpGaD
Norfloxacin—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.12e-05	0.000462	CcSEcCtD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	5.1e-05	0.00154	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.02e-05	0.00152	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	5e-05	0.00151	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	5e-05	0.00151	CbGpPWpGaD
Norfloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	4.96e-05	0.0015	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.95e-05	0.0015	CbGpPWpGaD
Norfloxacin—Vomiting—Prednisone—chronic obstructive pulmonary disease	4.92e-05	0.000444	CcSEcCtD
Norfloxacin—Rash—Prednisone—chronic obstructive pulmonary disease	4.88e-05	0.00044	CcSEcCtD
Norfloxacin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	4.87e-05	0.00044	CcSEcCtD
Norfloxacin—CYP3A7—Metabolism—APIP—chronic obstructive pulmonary disease	4.86e-05	0.00147	CbGpPWpGaD
Norfloxacin—Headache—Prednisone—chronic obstructive pulmonary disease	4.85e-05	0.000437	CcSEcCtD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.81e-05	0.00145	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	4.76e-05	0.00144	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	4.76e-05	0.00144	CbGpPWpGaD
Norfloxacin—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	4.75e-05	0.00144	CbGpPWpGaD
Norfloxacin—CYP1A1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.74e-05	0.00143	CbGpPWpGaD
Norfloxacin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	4.72e-05	0.00143	CbGpPWpGaD
Norfloxacin—SLC22A5—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	4.69e-05	0.00142	CbGpPWpGaD
Norfloxacin—CYP1A1—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.67e-05	0.00141	CbGpPWpGaD
Norfloxacin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	4.66e-05	0.00141	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.61e-05	0.0014	CbGpPWpGaD
Norfloxacin—Nausea—Prednisone—chronic obstructive pulmonary disease	4.6e-05	0.000415	CcSEcCtD
Norfloxacin—CYP3A5—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.55e-05	0.00138	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—APIP—chronic obstructive pulmonary disease	4.46e-05	0.00135	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.37e-05	0.00132	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.36e-05	0.00132	CbGpPWpGaD
Norfloxacin—CYP1A1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.36e-05	0.00132	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	4.31e-05	0.00131	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.31e-05	0.0013	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.31e-05	0.0013	CbGpPWpGaD
Norfloxacin—CYP1A1—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.3e-05	0.0013	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	4.18e-05	0.00127	CbGpPWpGaD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.97e-05	0.0012	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	3.96e-05	0.0012	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	3.88e-05	0.00117	CbGpPWpGaD
Norfloxacin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	3.82e-05	0.00116	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	3.7e-05	0.00112	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	3.54e-05	0.00107	CbGpPWpGaD
Norfloxacin—SLC22A6—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	3.54e-05	0.00107	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—APIP—chronic obstructive pulmonary disease	3.52e-05	0.00106	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	3.36e-05	0.00102	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	3.33e-05	0.00101	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—APIP—chronic obstructive pulmonary disease	3.32e-05	0.00101	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	3.26e-05	0.000987	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	3.25e-05	0.000984	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.22e-05	0.000975	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	3.19e-05	0.000965	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	3.19e-05	0.000965	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—GC—chronic obstructive pulmonary disease	3.13e-05	0.000949	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	3.13e-05	0.000947	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.06e-05	0.000927	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	3.04e-05	0.000919	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	3.04e-05	0.000919	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.02e-05	0.000915	CbGpPWpGaD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.99e-05	0.000906	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.98e-05	0.000902	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.95e-05	0.000894	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.91e-05	0.000882	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—GC—chronic obstructive pulmonary disease	2.87e-05	0.000869	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.86e-05	0.000867	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.8e-05	0.000846	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.78e-05	0.00084	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.76e-05	0.000835	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.74e-05	0.000829	CbGpPWpGaD
Norfloxacin—CYP2A6—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	2.72e-05	0.000822	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.67e-05	0.000808	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.63e-05	0.000797	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.6e-05	0.000786	CbGpPWpGaD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.38e-05	0.000721	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.37e-05	0.000717	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.33e-05	0.000706	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.33e-05	0.000705	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.3e-05	0.000696	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	2.27e-05	0.000686	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.2e-05	0.000666	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.18e-05	0.00066	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.14e-05	0.000649	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—GC—chronic obstructive pulmonary disease	2.14e-05	0.000648	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	2.12e-05	0.000641	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.11e-05	0.00064	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.11e-05	0.000637	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.03e-05	0.000615	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2e-05	0.000606	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.99e-05	0.000602	CbGpPWpGaD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.8e-05	0.000544	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.71e-05	0.000518	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—GCLC—chronic obstructive pulmonary disease	1.69e-05	0.000512	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.63e-05	0.000495	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.57e-05	0.000475	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.55e-05	0.000469	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CTGF—chronic obstructive pulmonary disease	1.54e-05	0.000467	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.51e-05	0.000457	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.42e-05	0.000431	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.42e-05	0.000428	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—TP53—chronic obstructive pulmonary disease	1.41e-05	0.000427	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.4e-05	0.000425	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.36e-05	0.000413	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.3e-05	0.000395	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.27e-05	0.000384	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.24e-05	0.000375	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	1.22e-05	0.00037	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.19e-05	0.000359	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.17e-05	0.000354	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.17e-05	0.000354	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.16e-05	0.00035	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	1.12e-05	0.000338	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.09e-05	0.00033	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.09e-05	0.000329	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.08e-05	0.000328	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.08e-05	0.000326	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.07e-05	0.000325	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.05e-05	0.000319	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.05e-05	0.000319	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.03e-05	0.000313	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.03e-05	0.000311	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.01e-05	0.000306	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1e-05	0.000303	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.79e-06	0.000296	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.72e-06	0.000294	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.48e-06	0.000287	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.58e-06	0.00026	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.46e-06	0.000256	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.1e-06	0.000245	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.99e-06	0.000242	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.88e-06	0.000239	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.47e-06	0.000226	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.46e-06	0.000226	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.45e-06	0.000225	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	7.37e-06	0.000223	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	7.03e-06	0.000213	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.87e-06	0.000208	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	6.73e-06	0.000204	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	6.72e-06	0.000203	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—ALB—chronic obstructive pulmonary disease	6.44e-06	0.000195	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—NOS3—chronic obstructive pulmonary disease	6.16e-06	0.000186	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.75e-06	0.000174	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	5.69e-06	0.000172	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	5.19e-06	0.000157	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.17e-06	0.000156	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.1e-06	0.000154	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	5.08e-06	0.000154	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	4.86e-06	0.000147	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—ALB—chronic obstructive pulmonary disease	4.8e-06	0.000145	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.78e-06	0.000145	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.75e-06	0.000144	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.59e-06	0.000139	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.5e-06	0.000136	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.99e-06	0.000121	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.93e-06	0.000119	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.67e-06	0.000111	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.47e-06	0.000105	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	3.06e-06	9.26e-05	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.93e-06	8.86e-05	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.36e-06	7.15e-05	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.26e-06	6.84e-05	CbGpPWpGaD
